|
|
Article: Geron Corporation to Present at Lazard Capital Markets Healthcare Conference.(Conference news)
- Article from:
- Business Wire
- Article date:
- November 27, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's product development programs at 2:00 p.m. EST on Wednesday, Nov. 28, 2007, at the Lazard Capital Markets 4th Annual Healthcare Conference in New York City.
The update will include information about Geron's portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company's human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), ...